SCHEMBL4311166

SCHEMBL4311166

O=C(NCc1cccs1)c1ccccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.50
POLB P06746 1/20 0.50
LMNA P02545 2/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
HSD17B10 Q99714 1/20 0.45
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
PSMD14 O00487 1/20 0.44
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
TTK P33981 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4311170 1.00 HPGD (0.50) HPGDPOLBLMNAMAPK1RAB9A
SCHEMBL958960 0.79 KDM4E (0.64) HPGDPOLBLMNARAB9AMEN1
SCHEMBL4307770 0.78 AURKA (0.62) HPGDPOLBRAB9AMEN1KMT2A
SCHEMBL4307765 0.78 AURKA (0.62) HPGDPOLBRAB9AMEN1KMT2A
SCHEMBL4317388 0.77 AURKA (0.51) KDM4ESMN1; SMN2GAAMAPTAURKA
SCHEMBL4317391 0.77 AURKA (0.51) KDM4ESMN1; SMN2GAAMAPTAURKA
SCHEMBL4313399 0.76 CYP1A2 (0.52) HPGDLMNAMAPK1RAB9AMEN1
SCHEMBL4313388 0.76 CYP1A2 (0.52) HPGDLMNAMAPK1RAB9AMEN1
SCHEMBL4308050 0.75 FLT3 (0.58) KDM4ESMN1; SMN2NPC1
SCHEMBL7665410 0.75 HPGD (0.59) HPGDPOLBLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 HPGD 4033/4885POLB 4393/4885LMNA 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.